Epidemiological and economic impact of pandemic influenza in Chicago: Priorities for vaccine interventions

The study objective is to estimate the epidemiological and economic impact of vaccine interventions during influenza pandemics in Chicago, and assist in vaccine intervention priorities. Scenarios of delay in vaccine introduction with limited vaccine efficacy and limited supplies are not unlikely in future influenza pandemics, as in the 2009 H1N1 influenza pandemic. We simulated influenza pandemics in Chicago using agent-based transmission dynamic modeling. Population was distributed among high-risk and non-high risk among 0–19, 20–64 and 65+ years subpopulations. Different attack rate scenarios for catastrophic (30.15%), strong (21.96%), and moderate (11.73%) influenza pandemics were compared against vaccine intervention scenarios, at 40% coverage, 40% efficacy, and unit cost of $28.62. Sensitivity analysis for vaccine compliance, vaccine efficacy and vaccine start date was also conducted. Vaccine prioritization criteria include risk of death, total deaths, net benefits, and return on investment. The risk of death is the highest among the high-risk 65+ years subpopulation in the catastrophic influenza pandemic, and highest among the high-risk 0–19 years subpopulation in the strong and moderate influenza pandemics. The proportion of total deaths and net benefits are the highest among the high-risk 20–64 years subpopulation in the catastrophic, strong and moderate influenza pandemics. The return on investment is the highest in the high-risk 0–19 years subpopulation in the catastrophic, strong and moderate influenza pandemics. Based on risk of death and return on investment, high-risk groups of the three age group subpopulations can be prioritized for vaccination, and the vaccine interventions are cost saving for all age and risk groups. The attack rates among the children are higher than among the adults and seniors in the catastrophic, strong, and moderate influenza pandemic scenarios, due to their larger social contact network and homophilous interactions in school. Based on return on investment and higher attack rates among children, we recommend prioritizing children (0–19 years) and seniors (65+ years) after high-risk groups for influenza vaccination during times of limited vaccine supplies. Based on risk of death, we recommend prioritizing seniors (65+ years) after high-risk groups for influenza vaccination during times of limited vaccine supplies.

[1]  L. Grohskopf,et al.  Prevention and Control of Influenza with Vaccines: Recommendations of the Advisory Committee on Immunization Practices, United States, 2015–16 Influenza Season , 2015, MMWR. Morbidity and mortality weekly report.

[2]  Matthew Biggerstaff,et al.  Epidemiology of 2009 pandemic influenza A (H1N1) in the United States. , 2011, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[3]  C. Fraser,et al.  Reducing the impact of the next influenza pandemic using household-based public health interventions. , 2006, Hong Kong medical journal = Xianggang yi xue za zhi.

[4]  A. Langworthy,et al.  An influenza simulation model for immunization studies. , 1976, American journal of epidemiology.

[5]  A. Monto,et al.  Effect of vaccination of a school-age population upon the course of an A2-Hong Kong influenza epidemic. , 1969, Bulletin of the World Health Organization.

[6]  G. Tomba,et al.  Estimating influenza latency and infectious period durations using viral excretion data. , 2012, Epidemics.

[7]  Madhav V. Marathe,et al.  EpiSimdemics: An efficient algorithm for simulating the spread of infectious disease over large realistic social networks , 2008, 2008 SC - International Conference for High Performance Computing, Networking, Storage and Analysis.

[8]  P. Piedra,et al.  Direct and indirect effectiveness of influenza vaccination delivered to children at school preceding an epidemic caused by 3 new influenza virus variants. , 2010, The Journal of infectious diseases.

[9]  M. Biggerstaff,et al.  Estimating the Potential Effects of a Vaccine Program Against an Emerging Influenza Pandemic—United States , 2015, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[10]  M. Hornbrook,et al.  Influenza Vaccination Programs for Elderly Persons: Cost-Effectiveness in a Health Maintenance Organization , 1994, Annals of Internal Medicine.

[11]  R. Borse,et al.  Effects of Vaccine Program against Pandemic Influenza A(H1N1) Virus, United States, 2009–2010 , 2013, Emerging infectious diseases.

[12]  Zhiwen Yu,et al.  Efficient Vaccine Distribution Based on a Hybrid Compartmental Model , 2016, PloS one.

[13]  I M Longini,et al.  Estimating household and community transmission parameters for influenza. , 1982, American journal of epidemiology.

[14]  S. Humiston,et al.  Cost of Universal Influenza Vaccination of Children in Pediatric Practices , 2009, Pediatrics.

[15]  Dimiter Dobrev,et al.  Computer Simulation , 1966, J. Inf. Process. Cybern..

[16]  C. Macken,et al.  Mitigation strategies for pandemic influenza in the United States. , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[17]  A. Gandjour.  Economic analysis of influenza vaccination and treatment. , 2003, Annals of internal medicine.

[18]  D C Dover,et al.  Pandemic Risk Assessment Model (PRAM): a mathematical modeling approach to pandemic influenza planning. , 2016, Epidemiology and infection.

[19]  J. Wallinga,et al.  Serial intervals of respiratory infectious diseases: a systematic review and analysis. , 2014, American journal of epidemiology.

[20]  Joel Huber,et al.  Economic Analysis of Influenza Vaccination and Antiviral Treatment for Healthy Working Adults , 2002, Annals of Internal Medicine.

[21]  M. Meltzer,et al.  An economic analysis of annual influenza vaccination of children. , 2005, Vaccine.

[22]  J. Hall,et al.  Cost of influenza hospitalization at a tertiary care children's hospital and its impact on the cost-benefit analysis of the recommendation for universal influenza immunization in children age 6 to 23 months. , 2005, The Journal of pediatrics.

[23]  M. Marathe,et al.  Economic and social impact of influenza mitigation strategies by demographic class. , 2011, Epidemics.

[24]  Standardizing Scenarios to Assess the Need to Respond to an Influenza Pandemic , 2015, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[25]  L. Mermel,et al.  Does Influenza Transmission Occur from Asymptomatic Infection or Prior to Symptom Onset? , 2009, Public health reports.

[26]  T. Lieu,et al.  Health Benefits, Risks, and Cost-Effectiveness of Influenza Vaccination of Children , 2006, Emerging infectious diseases.

[27]  Ivo M Foppa,et al.  Net Costs Due to Seasonal Influenza Vaccination — United States, 2005–2009 , 2015, PloS one.

[28]  Direct and indirect impact of influenza vaccination of young children on school absenteeism. , 2012, Vaccine.

[29]  Shawn T. Brown,et al.  A computer simulation of vaccine prioritization, allocation, and rationing during the 2009 H1N1 influenza pandemic. , 2010, Vaccine.

[30]  N. Cox,et al.  Prevention and control of seasonal influenza with vaccines: recommendations of the Advisory Committee on Immunization Practices (ACIP), 2009. , 2009 .

[31]  C. Bridges,et al.  The annual impact of seasonal influenza in the US: measuring disease burden and costs. , 2007, Vaccine.

[32]  N. Ferguson,et al.  Time lines of infection and disease in human influenza: a review of volunteer challenge studies. , 2008, American journal of epidemiology.

[33]  D. Cummings,et al.  Strategies for mitigating an influenza pandemic , 2006, Nature.

[34]  D. Wagener,et al.  Prevalence of high-risk indications for influenza vaccine varies by age, race, and income. , 2010, Vaccine.

[35]  Katherine E Atkins,et al.  Effect of mass paediatric influenza vaccination on existing influenza vaccination programmes in England and Wales: a modelling and cost-effectiveness analysis , 2017, The Lancet. Public health.

[36]  C. Furlanello,et al.  Mitigation Measures for Pandemic Influenza in Italy: An Individual Based Model Considering Different Scenarios , 2008, PloS one.

[37]  M E Halloran,et al.  Estimation of the efficacy of live, attenuated influenza vaccine from a two-year, multi-center vaccine trial: implications for influenza epidemic control. , 2000, Vaccine.

[38]  M. Biggerstaff,et al.  Novel Framework for Assessing Epidemiologic Effects of Influenza Epidemics and Pandemics , 2013, Emerging infectious diseases.

[39]  Carrie Reed,et al.  Influenza Illness and Hospitalizations Averted by Influenza Vaccination in the United States, 2005–2011 , 2013, PloS one.

[40]  M. Meltzer,et al.  Effectiveness and cost-benefit of influenza vaccination of healthy working adults: A randomized controlled trial. , 2000, JAMA.

[41]  M. Meltzer,et al.  Estimating medical practice expenses from administering adult influenza vaccinations. , 2005, Vaccine.

[42]  M. Meltzer,et al.  Influenza cost and cost-effectiveness studies globally--a review. , 2013, Vaccine.

[43]  C. Macken,et al.  Modeling targeted layered containment of an influenza pandemic in the United States , 2008, Proceedings of the National Academy of Sciences.

[44]  M. D. McKay,et al.  Creating synthetic baseline populations , 1996 .

[45]  C. Reed,et al.  Cost-Effectiveness of 2009 Pandemic Influenza A(H1N1) Vaccination in the United States , 2011, PloS one.

[46]  J. Medlock,et al.  Optimizing Influenza Vaccine Distribution , 2009, Science.

[47]  C. Barrett,et al.  Comparing Effectiveness of Top-Down and Bottom-Up Strategies in Containing Influenza , 2011, PloS one.

[48]  M. Meltzer,et al.  The economic impact of pandemic influenza in the United States: priorities for intervention. , 1999, Emerging infectious diseases.